AGOURA HILLS, California, Feb. 22, 2021 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for
Read more
AGOURA HILLS, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) — Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today
Read more
AGOURA HILLS, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today the receipt
Read more
Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s effort
Read more
The licensing agreement of OT-101 to Autotelic BIO with the field of use limited to OT-101 (Trabedersen) with Interleukin-2 (OT-101/IL-2)
Read more